The data suggest a systemic exclusion of women, individuals without relevant risk factors, and those at increased risk of adverse events, but data are limited and heavily weighted towards cardiovascular trials which commonly recruit (and report on) cardiovascular comorbidities/risk factors.
Abstract
Many people with a physical health condition are ineligible for randomised clinical trials (RCTs) of treatments for that condition. However, less is known about the differences in characteristics and outcomes between those that are eligible and ineligible for RCTs.
Systematic review without meta-analysis. Screened studies were those included in a previous review of trial eligibility (full-text rescreened for this study) and new studies identified in a Medline and Embase search from 12/02/18 to 13/04/23. Included studies were those which evaluated the proportion of patients in a real-world population eligible for one or more RCTs, which additionally compared eligible and ineligible patient characteristics. Titles and abstracts were screened by two reviewers independently and risk of bias assessed. Comparisons were demographic/clinical characteristics and outcome rates in real-world data (RWD). Median differences were compared using Wilcoxon signed rank.
Forty-nine studies examining 122 trials in 52 RWD sources were included. 34/49 studies examined cardiovascular trials (57/122 trials), seven examined cancer (30 trials), two musculoskeletal diseases (24 trials) and two respiratory diseases (11 trials). Risk of bias was high for 33 (67.3%) studies. The median proportion of women was higher in the trial-ineligible (39.0%) than trial-eligible (34.6%,
p
= 0.008, 63 trials). Comorbidities examined by the included studies were less common in the trial-ineligible (e.g. hypertension median prevalence 61.0% vs 66.0%;
p
= 0.03, 35 trials), but baseline condition severity was higher (median proportion with markers of more severe index disease 37.9% vs 33.5%,
p
= 0.02, 43 trials). No difference was found for age. All-cause mortality did not differ, but serious adverse events occurred more frequently in the trial-ineligible (median 12.9% vs 6.3%,
p
= 0.017, 14 trials).
The data suggest a systemic exclusion of women, individuals without relevant risk factors, and those at increased risk of adverse events, but data are limited and heavily weighted towards cardiovascular trials which commonly recruit (and report on) cardiovascular comorbidities/risk factors. There is a need for more systematic research examining the impact of trial-eligibility and recruitment on who is included in trials and evidence.
PROSPERO registration CRD42023415960. Registered on April 26, 2023. (
https://www.crd.york.ac.uk/PROSPERO/view/CRD42023415960
).
This review aims to synthesize recent studies on the efficacy of acceptance and commitment therapy (ACT) for older adults, both overall and for depression, anxiety, quality of life, and pain specifically. Studies were included if they evaluated ACT in a trial with an older adult population, reported pretreatment and po...
Jennifer Krafft, Carter H. Davis, M. Jacobs et al.· Psychology and Aging· 0 citations
Reporting of baseline characteristics in randomised controlled trials (RCTs) is necessary to provide a clear and complete picture of the participants studied. The aim of this review was to map existing review-level evidence examining the quality of reporting of participant characteristics in any element of trials...
A. Yakimova, C. Mcdaid, C. Welch et al.· Trials· 0 citations
BACKGROUND
Concerns persist regarding the applicability of randomized controlled trials (RCTs) on metastatic hormone-sensitive prostate cancer (mHSPC) to real-world clinical practice.
OBJECTIVE
We aimed to evaluate the generalizability of RCTs using data from PIONEER.
DESIGN, SETTING AND PARTICIPANTS
Trial eligibil...
G. Gandaglia, F. Pellegrino, A. Hijazy et al.· European Urology Focus· 0 citations
OBJECTIVES
Cluster-randomized clinical trials (cRCTs) are pooled with individually randomized clinical trials (iRCTs) in meta-analyses. However, cRCTs are associated with methodological characteristics potentially inducing systematic differences compared with iRCTs. In acute settings, trial inclusion is time-sensitive,...
Simon Lønstrup, P. Petersen, N. Bruun et al.· Critical Care Medicine· 0 citations
The available evidence suggests that non-pharmacological interventions may improve depressive symptoms, anxiety symptoms, and sleep quality in patients receiving MHD, but the certainty of evidence was low for anxiety and sleep quality outcomes and moderate for depressive symptoms, and these findings should be interpret...
Min-Jie Liu, Hai-Xia Chen, Yun-Yun Liu et al.· Frontiers in Public Health· 0 citations
Women remain underrepresented in HF RCTs and sex-stratified analyses suggest a potentially greater relative benefit of drug intervention in women, which might inform future RCTs.
L. Fazzini, L. Pascalis, C. Madaudo et al.· European Journal of Heart Fa...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.